Bio-Rad’s New ChemiDoc™ Touch Imaging System Surpasses Film’s Performance, Simplifies Western Blot Detection

Date: 
2014-09-18

Hercules, CA — September 18, 2014 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announces the launch of its ChemiDoc Touch Imaging System. This system is a significant advance in chemiluminescent western blot detection, surpassing the performance of film and the convenience of other digital imaging systems.

Until now, digital imaging systems failed to deliver the sensitivity and resolution of film. The new ChemiDoc Touch System, however, allows detection of faint bands missed by film and produces publication-quality images.

The ChemiDoc Touch Imaging System is better able than film to detect faint bands.

The ChemiDoc Touch System outperforms film in other ways as well. When using film to image abundant proteins, strong bands quickly saturate and become unquantifiable. Saturated bands can also obscure the signal from adjacent faint bands, making western blotting with film challenging. The ChemiDoc Touch System addresses these issues through its wide dynamic range, which permits easy and reliable quantitation even of highly abundant proteins, and through its ability to optimize exposure for each protein of interest.

Dr. Ernesto Diaz-Flores, PhD, an assistant adjunct professor at the University of California, San Francisco (UCSF), conducted early tests on the Bio-Rad product. Dr. Diaz-Flores used the imager to simultaneously measure protein expression level changes of up to 30 different proteins in samples from leukemia patients to understand how gene mutations alter protein pathways that might represent novel therapeutic targets.

Ernesto Diaz-Flores describes using the ChemiDoc Touch Imaging System to distinguish potential therapeutic targets in translational leukemia research.

“My goal in collaborating on this project with Bio-Rad was to help develop the next generation technology required to advance protein quantification analysis and its impact in research,” said Dr. Diaz-Flores. “We found that the technology outperformed film and other imaging technologies, as it allows us to simultaneously visualize and quantitate both high and low expression proteins in a matter of seconds. It also allowed us to determine fold induction or protein reduction in high resolution and correlate these levels to drug response in multiple protein assays in a time-efficient manner.”

Capturing images with the ChemiDoc Touch System is easy. Unlike the often sluggish response of other imagers, the ChemiDoc Touch System offers a smooth, intuitive user experience that makes capturing, reviewing, selecting, and exporting images efficient and straightforward.

The imager also allows stain-free imaging, a technology exclusive to Bio-Rad. Using the stain-free enabled V3 Western Workflow™, researchers can quickly determine whether their western blot is proceeding as planned using the imager at multiple built-in checkpoints. Researchers can also use stain-free technology to perform total protein normalization for easier and more reliable protein quantitation.

To learn more about the ChemiDoc Touch System and how it provides a better user experience than film, visit www.bio-rad.com/ChemiDocTouchPR.

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs approximately 7,750 people worldwide and had revenues exceeding $2.1 billion in 2013. For more information, visit our website at www.bio-rad.com.

The information stated above was prepared by Bio-Rad Laboratories to report the outcome of research conducted on its product and reflects solely the opinion of Dr. Ernesto Diaz-Flores. Nothing in this statement shall be construed to imply any support or endorsement of Bio-Rad Laboratories or any of its products, by the Regents of the University of California, its officers, agents, and employees.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.

Press Contacts:
Kris Simonyi
Bio-Rad Laboratories, Inc.
510-741-1000
kris_simonyi@bio-rad.com

Ken Li
Chempetitive Group
312-997-2436 x112
kli@chempetitive.com